Physician profile
Leonard D Kim
NPI 1730103748
$53,393.23
in general payments reported to CMS, 2019-2025
14 companies · $171 in 2025
The $171 reported for 2025 was more than what 78% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $109 · 2021: $26K · 2022: $11K · 2023: $127 · 2024: $4,684 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,000 · Travel and Lodging: $558 · Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,000.00 |
| Travel and Lodging | $558.20 |
| Food and Beverage | $423.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $36,262.26 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $11,325.37 | 2019 | |
| Eagle Pharmaceuticals, INC. | $4,579.61 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $346.57 | 2022 | |
| Allergan, INC. | $188.16 | 2019-2021 | |
| Abbvie INC. | $143.03 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $125.80 | 2024 | Rebyota |
| Vertex Pharmaceuticals Incorporated | $117.58 | 2025 | |
| Merck Sharp & Dohme LLC | $105.79 | 2019 | |
| Mallinckrodt Hospital Products INC. | $82.85 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $41.36 | 2021-2023 | Exparel |
| Janssen Biotech, INC. | $37.81 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $19.57 | 2019 | |
| Cook Medical LLC | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.